COPENHAGEN, Denmark, June 11, 2021 – Bavarian Nordic A/S (OMX: BAVA) introduced at the moment that the Firm was lately engaged by Public Health England (PHE) and the Medicines and Health Merchandise Regulatory Company (MHRA) to produce its IMVANEX® smallpox vaccine in response to new circumstances of monkeypox in the UK. Two associated circumstances had been confirmed and admitted to a hospital in Liverpool. One was probably contaminated in Africa, the place the household arrived from a couple of days earlier than onset of illness, and a sibling case probably contaminated on UK soil by the primary case.
Monkeypox is a uncommon, however severe illness, which is endemic in Central and West Africa. The illness is sort of just like human smallpox, though it’s much less extreme with an estimated fatality price of 1-10%.
IMVANEX (MVA-BN) is accepted by the European Fee for lively immunization in opposition to smallpox however has additionally obtained approval for monkeypox by the U.S. Meals and Drug Administration (FDA) and Health Canada, as the one vaccine accepted for this indication in these territories. Bavarian Nordic beforehand delivered IMVANEX to PHE in reference to the primary human circumstances of monkeypox in the UK in 2018 and later in 2019, when a number of unrelated human circumstances had been imported from Nigeria with a subsequent an infection of a healthcare employee in the UK.
Paul Chaplin, President and CEO of Bavarian Nordic stated: “We’re happy to help Public Health England quickly in such an emergency scenario. Vaccination is a vital measure to forestall and management the unfold of ailments globally. Governments have a necessary position in getting ready for outbreaks by stockpiling vaccines and coverings in order that they’re available in occasions like this. We now have an extended historical past of working with different governments on strengthening their nationwide preparedness in outbreak conditions, and we urge extra international locations to actively take into account and mitigate the dangers of ailments like monkeypox, which sadly is on the rise in Africa and has in current years proven to cross borders a number of occasions.”
About Bavarian Nordic
Bavarian Nordic is a totally built-in vaccines firm targeted on the event, manufacture and commercialization of life-saving vaccines. We’re a worldwide chief in smallpox vaccines and have been a long-term provider to the U.S. Authorities of a non-replicating smallpox vaccine, which has been accepted by the FDA beneath the commerce identify JYNNEOS®, additionally for the safety in opposition to monkeypox. The vaccine is accepted as a smallpox vaccine in Europe beneath the commerce identify IMVANEX® and in Canada beneath the commerce identify IMVAMUNE®. Our business product portfolio moreover comprises the market-leading vaccine Rabipur®/RabAvert® in opposition to rabies and Encepur® in opposition to tick-borne encephalitis. Utilizing our reside virus vaccine platform expertise, MVA-BN®, we now have created a various portfolio of proprietary and partnered product candidates designed to save lots of and enhance lives by unlocking the ability of the immune system, together with an Ebola vaccine, MVABEA®, which is licensed to the Janssen Pharmaceutical Firms of Johnson & Johnson. We’re additionally dedicated to the event of a subsequent era COVID-19 vaccine primarily based on an in-licensed capsid virus-like particle expertise. The vaccine candidate, ABNCoV2, is at present being investigated in medical trials. For extra data go to www.bavarian-nordic.com.
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, email@example.com, Tel: +1 781 686 9600